Abstract
While influenza remains a major threat to public health, researchers continue to search for a universal solution to improving the efficacy of the influenza vaccine. Even though influenza affects people of all different ages, it can be extremely hazardous to people of 65 years of age or older since that is the population that makes up the high majority of the death toll caused by influenza-related diseases. Elderly individuals suffer the effects of immunosenescence as they age, which is the diminishing of the overall immune response. Immunosenescence occurs by specifically affecting the adaptive immune response which controls the establishment of immunity after vaccination or infection. There are many studies under way that are trying to find a resolution to the problem of the influenza vaccine not providing enough protection in the elderly population. One of the possible strategies is to seek the use of an optimal adjuvant, an immunological agent that can enhance immune responses, with the current vaccine formulation. Here, we used the murine model to review the effects of adjuvants on the antibody response to influenza vaccines in aged mice. Since adjuvants can enhance the production of important inflammatory cytokines and activation of dendritic cells, the stimulation of these cells are boosted to increase the effectiveness of the influenza vaccine in aged mice which would hopefully translate to the elderly.
Article PDF
Similar content being viewed by others
References
Asanuma H, Hirokawa K, Uchiyama M, Suzuki Y, Aizawa C, Kurata T, Sata T, Tamura S (2001). Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine. Vaccine, 19(28–29): 3981–3989
Camilloni B, Neri M, Lepri E, Basileo M, Sigismondi N, Puzelli S, Donatelli I, Iorio A M (2010). An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine, 28(47): 7536–7541
Centers for Disease Control and Prevention (CDC) (2013)(2). Influenza Activity-United States, 2012–13
Centers for Disease Control and Prevention (CDC) (2013)(1). Estimated influenza illnesses and hospitalizations averted by influenza vaccination-United States, 2012–13 influenza season. MMWR Morb Mortal Wkly Rep, 62(49): 997–1000
Centers for Disease Control and Prevention (CDC) (2013–14). Influenza activity-United States, 2012–13 season and composition of the 2013–14 influenza vaccine. MMWR Morb Mortal Wkly Rep, 62(23): 473–479
Chan T C, Hung I F, Luk J K, Shea Y F, Chan F H, Woo P C, Chu L W (2011). Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: a oneyear prospective cohort study. Vaccine, 29(44): 7773–7778
Chen W H, Kozlovsky B F, Effros R B, Grubeck-Loebenstein B, Edelman R, Sztein M B (2009). Vaccination in the elderly: an immunological perspective. Trends Immunol, 30(7): 351–359
Deans G D, Stiver H G, McElhaney J E (2010). Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med, 267(2): 220–227
Diebold S S, Kaisho T, Hemmi H, Akira S, Reise Sousa C (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 303(5663): 1529–1531
Dorrington M G, Bowdish D M E (2013). Immunosenescence and novel vaccination strategies for the elderly. Front Immunol, 4: 171
Fiore A E, Uyeki T M, Broder K, Finelli L, Euler G L, Singleton J A, Iskander J K, Wortley P M, Shay D K, Bresee J S, Cox N J, and the Centers for Disease Control and Prevention (CDC) (2010). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep, 59(RR-8): 1–62
Fisher E M, Jiang J (2012). Adjuvanted vaccines against influenza in the elderly. Front Biol, 7(3): 221–226
Forrest B D, Steele A D, Hiemstra L, Rappaport R, Ambrose C S, Gruber W C (2011). A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine, 29(20): 3633–3639
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G (2000). Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci, 908(1): 244–254
Goronzy J J, Weyand C M (2013). Understanding immunosenescence to improve responses to vaccines. Nat Immunol, 14(5): 428–436
Gorse G J, Campbell M J, Otto E E, Powers D C, Chambers G W, Newman F K (1995). Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis, 172(1): 1–10
Janeway C A Jr, Medzhitov R (2002). Innate immune recognition. Annu Rev Immunol, 20(1): 197–216
Katz J M, Lu X, Todd C W, Newman M J (2000). A nonionic block copolymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine, 18(21): 2177–2187
Keitel W A, Atmar R L, Cate T R, Petersen N J, Greenberg S B, Ruben F, Couch R B (2006). Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med, 166(10): 1121–1127
Lambert N D, Ovsyannikova I G, Pankratz V S, Jacobson RM, Poland G A (2012). Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines, 11(8): 985–994
Lee B Y, Ercius A K, Smith K J (2009). A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine, 27(16): 2251–2257
Lelic A, Verschoor C P, Ventresca M, Parsons R, Evelegh C, Bowdish D, Betts M R, Loeb M B, Bramson J L (2012). The polyfunctionality of human memory CD8 + T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog, 8(12): e1003076
MacDonald A J, Cao L, He Y, Zhao Q, Jiang S, Lustigman S (2005). rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine, 23(26): 3446–3452
McElhaney J E, Effros R B (2009). Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol, 21(4): 418–424
McKee A S, Munks M W, Marrack P (2007). How do adjuvants work? Important considerations for new generation adjuvants. Immunity, 27(5): 687–690
Olivieri F, Rippo M R, Prattichizzo F, Babini L, Graciotti L, Recchioni R, Procopio A D (2013). Toll like receptor signaling in “inflammaging”: microRNA as new players. Immun Ageing, 10(1): 11
Podda A (2001). The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine, 19(17–19): 2673–2680
Rappuoli R, Mandl C W, Black S, De Gregorio E (2011). Vaccines for the twenty-first century society. Nat Rev Immunol, 11(12): 865–872
Ruf B R, Colberg K, Frick M, Preusche A (2004). Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection, 32(4): 191–198
Rümke H C, Richardus J H, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L (2013). Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis, 13(1): 348
Schneider-Ohrum K, Giles B M, Weirback H K, Williams B L, DeAlmeida D R, Ross TM (2011). Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine, 29(48): 9081–9092
Sullivan S J, Jacobson R, Poland G A (2010). Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines, 9(10): 1127–1133
Tawe W, Pearlman E, Unnasch T R, Lustigman S (2000). Angiogenic activity of Onchocerca volvulus recombinant proteins similar to vespid venom antigen 5. Mol Biochem Parasitol, 109(2): 91–99
Thompson WW, Moore MR, Weintraub E, Cheng P Y, Jin X, Bridges C B, Bresee J S, Shay D K (2009). Estimating influenza-associated deaths in the United States. Am J Public Health, 99(S2 Suppl 2): S225–S230
Tollervey J R, Lunyak V V (2012). Epigenetics: judge, jury and executioner of stem cell fate. Epigenetics, 7(8): 823–840
Triozzi P L, Stevens V C, Aldrich W, Powell J, Todd CW, Newman MJ (1997). Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer. Clin Cancer Res, 3(12 Pt 1): 2355–2362
Van Zant G, Liang Y (2012). Concise review: hematopoietic stem cell aging, life span, and transplantation. Stem Cells Transl Med, 1(9): 651–657
Xiao W, Du L, Liang C, Guan J, Jiang S, Lustigman S, He Y, Zhou Y (2008). Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine, 26(39): 5022–5029
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Concannon, M.A., Jiang, J. The effect of adjuvants on vaccine-induced antibody response against influenza in aged mice. Front. Biol. 9, 89–94 (2014). https://doi.org/10.1007/s11515-014-1301-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11515-014-1301-7